ClinicalTrials.gg
CompletedNCT00391872PLATOUpdated Mar 13, 2012Results posted

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

A Phase 3 interventional study of Ticagrelor and Clopidogrel in Acute Coronary Syndrome, sponsored by AstraZeneca. Completed at 672 sites in 44 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-03-13.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
18,624
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies testing ticagrelor in Acute Coronary Syndrome — 6 open to participants now, 8 under way, 1 of them phase 3. Ticagrelor · Acute Coronary Syndrome.

Enrollment
2nd of 67
18,624 · median 120
Started
2006
the only one that year
Phase 3
16 of 67
1 open now
Registered
1st of 67
by date
Lead sponsor
8 of 67
AstraZeneca

Among the 67 studies testing ticagrelor in Acute Coronary Syndrome, this one is the 2nd largest by enrollment, is the only one that started in 2006, is one of 16 in phase 3, and was the 1st registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

6 of the 67 studies testing ticagrelor in Acute Coronary Syndrome are open now, in 7 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About ticagrelor

Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing ticagrelor in Acute Coronary Syndrome, or all of them as a file.
02

Study summary

Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots. Ticagrelor is being developed as a treatment for patients with acute coronary syndrome (ACS). ACS is a term that is used to describe both heart attacks in progress or the imminent threat of a heart attack. ACS is usually caused by the formation of a blood clot in an artery that partially or totally blocks the blood supply to a portion of the heart muscle. Ticagrelor will be compared with clopidogrel to determine which drug, when either is used in conjunction with aspirin, is better at reducing deaths from vascular causes, future heart attacks and/or strokes in patients with ACS.

03

Conditions studied

  • Acute Coronary Syndrome

Keywords

  • ACS
  • Acute coronary syndrome
  • Heart attack
  • Unstable angina
  • Coronary artery disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female 18 years or older who has been hospitalised for chest pain and potential ACS
  • Females of must have a negative pregnancy test at enrollment and be willing to use 2 methods of reliable

Exclusion criteria

Exclusion Criteria:

  • Persons with moderate or severe liver disease
  • Persons who have already been treated with an invasive (angioplasty) procedure for the current episode of ACS
  • Persons who are being treated with blood clotting agents that cannot be stopped
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
18,624 participants (actual)

Study arms

  • Active comparator
    Clopidogrel

    Oral treatment

    Drug: Clopidogrel

  • Experimental
    Ticagrelor

    Oral treatment

    Drug: Ticagrelor

Interventions

  • Ticagrelor (AZD6140) 90 mg twice daily dose (BD)

    Also known as: AZD6140

  • Clopidogrel 75 mg once daily dose (ODD)

    Also known as: Plavix®

06

What researchers measure

Primary outcomes

  1. Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke

    Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee.

    Time frame: Randomization up to 12 months

  2. Participants With Any Major Bleeding Event

    Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee.

    Time frame: First dosing up to 12 months

Secondary outcomes

  1. Participants With Any Event From the Composite of Death From Vascular Causes, MI, and Stroke for the Subgroup of Patients With Intent for Invasive Management at Randomization

    Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee.

    Time frame: Randomization up to 12 months

  2. Participants With Any Event From the Composite of All-cause Mortality, MI, and Stroke

    Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee.

    Time frame: Randomization up to 12 months

  3. Participants With Any Event From the Composite of Death From Vascular Causes, MI (Including Silent), Stroke, Recurrent Ischemia, Transient Ischemic Attack (TIA) and Other Arterial Thrombotic Events.

    Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated.

    Time frame: Randomization up to 12 months

  4. Participants With MI Event

    Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee.

    Time frame: Randomization up to 12 months

  5. Participants With Death From Vascular Causes

    Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee.

    Time frame: Randomization up to 12 months

  6. Participants With Stroke

    Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee.

    Time frame: Randomization up to 12 months

  7. Participants With Death From Any Cause

    Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee.

    Time frame: Randomization up to 12 months

  8. Participants With Non-CABG (Coronary Artery Bypass Graft) Related Major Bleeding

    Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee.

    Time frame: First dosing up to 12 months

  9. Participants With Major or Minor Bleeding

    Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee.

    Time frame: First dosing up to 12 months

  10. Participants With Non-procedural Major Bleeding

    Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee.

    Time frame: First dosing up to 12 months

  11. Participants With Coronary Artery Bypass Graft (CABG) Major Bleeding

    Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds.

    Time frame: First dosing up to 12 months

  12. Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding

    Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds.

    Time frame: First dosing up to 12 months

  13. Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24-hour ECG Recorders for 1 Week Following Randomization

    Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists.

    Time frame: 1-week period following randomization

  14. Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24 Hour ECG Recorders for 1 Week at 1 Month Following Randomization

    Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists.

    Time frame: 1-week period following randomization

07

Results

Posted Mar 13, 2012

Participant flow

The first participant was enrolled on 11 October 2006 and the last participant completed the study on 27 February 2009. Study participants were randomized from 855 centers in 43 countries.

Participant flow — Overall Study
MilestoneTICAGRELORCLOPIDOGREL
Started93339291
Completed90269036
Not completed307255
Withdrew: Protocol violation72
Withdrew: Withdrawal by subject296249
Withdrew: Reason unknown24
Withdrew: Lost to follow-up20

Outcome measures

PrimaryParticipants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke

Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee.

Time frame:
Randomization up to 12 months
Reported as:
Number · Participants
Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke
ParticipantsTICAGRELORCLOPIDOGREL
Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke8641014
PrimaryParticipants With Any Major Bleeding Event

Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee.

Time frame:
First dosing up to 12 months
Reported as:
Number · Participants
Participants With Any Major Bleeding Event
ParticipantsTICAGRELORCLOPIDOGREL
Participants With Any Major Bleeding Event961929
SecondaryParticipants With Any Event From the Composite of Death From Vascular Causes, MI, and Stroke for the Subgroup of Patients With Intent for Invasive Management at Randomization

Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee.

Time frame:
Randomization up to 12 months
Reported as:
Number · Participants
Participants With Any Event From the Composite of Death From Vascular Causes, MI, and Stroke for the Subgroup of Patients With Intent for Invasive Management at Randomization
ParticipantsTICAGRELORCLOPIDOGREL
Participants With Any Event From the Composite of Death From Vascular Causes, MI, and Stroke for the Subgroup of Patients With Intent for Invasive Management at Randomization569668
SecondaryParticipants With Any Event From the Composite of All-cause Mortality, MI, and Stroke

Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee.

Time frame:
Randomization up to 12 months
Reported as:
Number · Participants
Participants With Any Event From the Composite of All-cause Mortality, MI, and Stroke
ParticipantsTICAGRELORCLOPIDOGREL
Participants With Any Event From the Composite of All-cause Mortality, MI, and Stroke9011065
SecondaryParticipants With Any Event From the Composite of Death From Vascular Causes, MI (Including Silent), Stroke, Recurrent Ischemia, Transient Ischemic Attack (TIA) and Other Arterial Thrombotic Events.

Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated.

Time frame:
Randomization up to 12 months
Reported as:
Number · Participants
Participants With Any Event From the Composite of Death From Vascular Causes, MI (Including Silent), Stroke, Recurrent Ischemia, Transient Ischemic Attack (TIA) and Other Arterial Thrombotic Events.
ParticipantsTICAGRELORCLOPIDOGREL
Participants With Any Event From the Composite of Death From Vascular Causes, MI (Including Silent), Stroke, Recurrent Ischemia, Transient Ischemic Attack (TIA) and Other Arterial Thrombotic Events.12901456
SecondaryParticipants With MI Event

Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee.

Time frame:
Randomization up to 12 months
Reported as:
Number · Participants
Participants With MI Event
ParticipantsTICAGRELORCLOPIDOGREL
Participants With MI Event504593
SecondaryParticipants With Death From Vascular Causes

Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee.

Time frame:
Randomization up to 12 months
Reported as:
Number · Participants
Participants With Death From Vascular Causes
ParticipantsTICAGRELORCLOPIDOGREL
Participants With Death From Vascular Causes353442
SecondaryParticipants With Stroke

Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee.

Time frame:
Randomization up to 12 months
Reported as:
Number · Participants
Participants With Stroke
ParticipantsTICAGRELORCLOPIDOGREL
Participants With Stroke125106
SecondaryParticipants With Death From Any Cause

Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee.

Time frame:
Randomization up to 12 months
Reported as:
Number · Participants
Participants With Death From Any Cause
ParticipantsTICAGRELORCLOPIDOGREL
Participants With Death From Any Cause399506
SecondaryParticipants With Non-CABG (Coronary Artery Bypass Graft) Related Major Bleeding

Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee.

Time frame:
First dosing up to 12 months
Reported as:
Number · Participants
Participants With Non-CABG (Coronary Artery Bypass Graft) Related Major Bleeding
ParticipantsTICAGRELORCLOPIDOGREL
Participants With Non-CABG (Coronary Artery Bypass Graft) Related Major Bleeding362306
SecondaryParticipants With Major or Minor Bleeding

Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee.

Time frame:
First dosing up to 12 months
Reported as:
Number · Participants
Participants With Major or Minor Bleeding
ParticipantsTICAGRELORCLOPIDOGREL
Participants With Major or Minor Bleeding13391215
SecondaryParticipants With Non-procedural Major Bleeding

Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee.

Time frame:
First dosing up to 12 months
Reported as:
Number · Participants
Participants With Non-procedural Major Bleeding
ParticipantsTICAGRELORCLOPIDOGREL
Participants With Non-procedural Major Bleeding235180
SecondaryParticipants With Coronary Artery Bypass Graft (CABG) Major Bleeding

Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds.

Time frame:
First dosing up to 12 months
Reported as:
Number · Participants
Participants With Coronary Artery Bypass Graft (CABG) Major Bleeding
ParticipantsTICAGRELORCLOPIDOGREL
Participants With Coronary Artery Bypass Graft (CABG) Major Bleeding619654
SecondaryParticipants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding

Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds.

Time frame:
First dosing up to 12 months
Reported as:
Number · Participants
Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding
ParticipantsTICAGRELORCLOPIDOGREL
Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding329341
SecondaryParticipants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24-hour ECG Recorders for 1 Week Following Randomization

Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists.

Time frame:
1-week period following randomization
Reported as:
Number · Participants
Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24-hour ECG Recorders for 1 Week Following Randomization
ParticipantsTICAGRELORCLOPIDOGREL
Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24-hour ECG Recorders for 1 Week Following Randomization8451
SecondaryParticipants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24 Hour ECG Recorders for 1 Week at 1 Month Following Randomization

Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists.

Time frame:
1-week period following randomization
Reported as:
Number · Participants
Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24 Hour ECG Recorders for 1 Week at 1 Month Following Randomization
ParticipantsTICAGRELORCLOPIDOGREL
Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24 Hour ECG Recorders for 1 Week at 1 Month Following Randomization2116

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TICAGRELOR———
CLOPIDOGREL———
Most frequent serious events
Showing 10 of 1,006
Most frequent serious events
EventTICAGRELORCLOPIDOGREL
Cardiac FailureCardiac disorders122/9333129/9291
Non-Cardiac Chest PainGeneral disorders101/9333103/9291
PneumoniaInfections and infestations69/933395/9291
Cerebrovascular AccidentNervous system disorders75/933350/9291
DyspnoeaRespiratory, thoracic and mediastinal disorders75/933350/9291
Atrial FibrillationCardiac disorders70/933368/9291
Cardiogenic ShockCardiac disorders60/933366/9291
Ventricular FibrillationCardiac disorders48/933364/9291
Chest PainGeneral disorders54/933363/9291
Thrombosis In DeviceInjury, poisoning and procedural complications35/933357/9291
Most frequent other events
Most frequent other events
EventTICAGRELORCLOPIDOGREL
DyspnoeaRespiratory, thoracic and mediastinal disorders1106/9333623/9291
HeadacheNervous system disorders621/9333565/9291
EpistaxisRespiratory, thoracic and mediastinal disorders566/9333317/9291
CoughRespiratory, thoracic and mediastinal disorders490/9333467/9291

Baseline characteristics

Age Continuous
Age Continuous(years)TICAGRELORCLOPIDOGRELTotal
Mean62.1 ± 11.2162.3 ± 11.2162.2 ± 22.42
Sex: Female, Male
Sex: Female, Male(Participants)TICAGRELORCLOPIDOGRELTotal
Female265526335288
Male6678665813336
08

Study locations

672 sites
  • Research Site
    Birmingham, Alabama, United States
  • Research Site
    Huntsville, Alabama, United States
  • Research Site
    Mobile, Alabama, United States
  • Research Site
    Tucson, Arizona, United States
  • Research Site
    Bakersfield, California, United States
  • Research Site
    Beverly Hills, California, United States
  • Research Site
    Burbank, California, United States
  • Research Site
    Healdsburg, California, United States
  • Research Site
    Los Angeles, California, United States
  • Research Site
    Roseville, California, United States
  • Research Site
    Sacramento, California, United States
  • Research Site
    San Diego, California, United States
  • Research Site
    Torrance, California, United States
  • Research Site
    Fort Collins, Colorado, United States
  • Research Site
    Danbury, Connecticut, United States
  • Research Site
    Hartford, Connecticut, United States
  • Research Site
    Newark, Delaware, United States
  • Research Site
    Washington, District of Columbia, United States
  • Research Site
    Atlantis, Florida, United States
  • Research Site
    Daytona Beach, Florida, United States
  • Research Site
    Ft. Lauderdale, Florida, United States
  • Research Site
    Hollywood, Florida, United States
  • Research Site
    Jacksonville, Florida, United States
  • Research Site
    Jupiter, Florida, United States
  • Research Site
    Melbourne, Florida, United States
  • Research Site
    Miami Beach, Florida, United States
  • Research Site
    Ocala, Florida, United States
  • Research Site
    Orlando, Florida, United States
  • Research Site
    Ormond Beach, Florida, United States
  • Research Site
    Pensacola, Florida, United States
  • Research Site
    Sarasota, Florida, United States
  • Research Site
    St Petersburg, Florida, United States
  • Research Site
    Chicago, Illinois, United States
  • Research Site
    Park Ridge, Illinois, United States
  • Research Site
    Rock Island, Illinois, United States
  • Research Site
    Rockford, Illinois, United States
  • Research Site
    Indianapolis, Indiana, United States
  • Research Site
    Muncie, Indiana, United States
  • Research Site
    Valparaiso, Indiana, United States
  • Research Site
    Iowa City, Iowa, United States
  • Research Site
    West Des Moines, Iowa, United States
  • Research Site
    Kansas City, Kansas, United States
  • Research Site
    Olathe, Kansas, United States
  • Research Site
    Ashland, Kentucky, United States
  • Research Site
    Louisville, Kentucky, United States
  • Research Site
    Shreveport, Louisiana, United States
  • Research Site
    Auburn, Maine, United States
  • Research Site
    Bangor, Maine, United States
  • Research Site
    Baltimore, Maryland, United States
  • Research Site
    Bethesda, Maryland, United States
  • Research Site
    Salisbury, Maryland, United States
  • Research Site
    Boston, Massachusetts, United States
  • Research Site
    Springfield, Massachusetts, United States
  • Research Site
    Ann Arbor, Michigan, United States
  • Research Site
    Kalamazoo, Michigan, United States
  • Research Site
    Lansing, Michigan, United States
  • Research Site
    Laper, Michigan, United States
  • Research Site
    Pontiac, Michigan, United States
  • Research Site
    Royal Oak, Michigan, United States
  • Research Site
    Saginaw, Michigan, United States
  • Research Site
    Troy, Michigan, United States
  • Research Site
    Ypsilanti, Michigan, United States
  • Research Site
    Duluth, Minnesota, United States
  • Research Site
    Minneapolis, Minnesota, United States
  • Research Site
    St Paul, Minnesota, United States
  • Research Site
    Tupelo, Mississippi, United States
  • Research Site
    Columbia, Missouri, United States
  • Research Site
    Joplin, Missouri, United States
  • Research Site
    Kansas City, Missouri, United States
  • Research Site
    St Louis, Missouri, United States
  • Research Site
    Lincoln, Nebraska, United States
  • Research Site
    Omaha, Nebraska, United States
  • Research Site
    Papillion, Nebraska, United States
  • Research Site
    Newark, New Jersey, United States
  • Research Site
    Oakland, New Jersey, United States
  • Research Site
    Paterson, New Jersey, United States
  • Research Site
    Albuquerque, New Mexico, United States
  • Research Site
    Brooklyn, New York, United States
  • Research Site
    Buffalo, New York, United States
  • Research Site
    Johnson City, New York, United States
  • Research Site
    Kingston, New York, United States
  • Research Site
    New Hartford, New York, United States
  • Research Site
    New York, New York, United States
  • Research Site
    Rochester, New York, United States
  • Research Site
    Syracuse, New York, United States
  • Research Site
    Williamsville, New York, United States
  • Research Site
    Chapel Hill, North Carolina, United States
  • Research Site
    Charlotte, North Carolina, United States
  • Research Site
    Greensboro, North Carolina, United States
  • Research Site
    High Point, North Carolina, United States
  • Research Site
    Raleigh, North Carolina, United States
  • Research Site
    Winston-salem, North Carolina, United States
  • Research Site
    Cleveland, Ohio, United States
  • Research Site
    Columbus, Ohio, United States
  • Research Site
    Kettering, Ohio, United States
  • Research Site
    Zanesville, Ohio, United States
  • Research Site
    Oklahoma City, Oklahoma, United States
  • Research Site
    Tulsa, Oklahoma, United States
  • Research Site
    Bend, Oregon, United States
  • Research Site
    Camp Hill, Pennsylvania, United States

Showing the first 100 of 672 sites across 44 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Natale P, Palmer SC, Saglimbene VM, Ruospo M, Razavian M, Craig JC, Jardine MJ, Webster AC, Strippoli GF. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev. 2022 Feb 28;2(2):CD008834. doi: 10.1002/14651858.CD008834.pub4. PubMed 35224730 ↗
  • Samman KN, Mehanna P, Takla E, Grenier JC, Chan MY, Lopes RD, Neely ML, Wang TY, Newby LK, Becker RC, Lordkipanidze M, Ruiz M, Hussin JG, Jolicoeur EM. Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel. Cell Rep Med. 2021 Jun 4;2(6):100299. doi: 10.1016/j.xcrm.2021.100299. eCollection 2021 Jun 15. PubMed 34195679 ↗
  • Thi Thu Nguyen T, Van Do D, Mellstrom C, Quang Nguyen T, Manh Pham H, Van Hoang S, Cong Luu T, Le Phuong T. Cost-Effectiveness of Ticagrelor Compared with Clopidogrel in Patients with Acute Coronary Syndrome from Vietnamese Healthcare Payers' Perspective. Adv Ther. 2021 Jul;38(7):4026-4039. doi: 10.1007/s12325-021-01743-5. Epub 2021 Jun 11. PubMed 34115329 ↗
  • Mahmoodi BK, Eriksson N, Vos GJA, Meijer K, Siegbahn A, James S, Wallentin L, Ten Berg JM. Factor V Leiden Does Not Modify the Phenotype of Acute Coronary Syndrome or the Extent of Myocardial Necrosis. J Am Heart Assoc. 2021 Jun;10(11):e020025. doi: 10.1161/JAHA.120.020025. Epub 2021 May 17. PubMed 33998271 ↗
  • Gregersen I, Michelsen AE, Lunde NN, Akerblom A, Lakic TG, Skjelland M, Ryeng Skagen K, Becker RC, Lindback J, Himmelmann A, Solberg R, Johansen HT, James SK, Siegbahn A, Storey RF, Kontny F, Aukrust P, Ueland T, Wallentin L, Halvorsen B. Legumain in Acute Coronary Syndromes: A Substudy of the PLATO (Platelet Inhibition and Patient Outcomes) Trial. J Am Heart Assoc. 2020 Sep;9(17):e016360. doi: 10.1161/JAHA.120.016360. Epub 2020 Aug 15. PubMed 32809893 ↗
  • Sumaya W, Wallentin L, James SK, Siegbahn A, Gabrysch K, Himmelmann A, Ajjan RA, Storey RF. Impaired Fibrinolysis Predicts Adverse Outcome in Acute Coronary Syndrome Patients with Diabetes: A PLATO Sub-Study. Thromb Haemost. 2020 Mar;120(3):412-422. doi: 10.1055/s-0039-1701011. Epub 2020 Jan 23. PubMed 31975352 ↗
  • Ueland T, Akerblom A, Ghukasyan T, Michelsen AE, Becker RC, Bertilsson M, Budaj A, Cornel JH, Himmelmann A, James SK, Siegbahn A, Storey RF, Kontny F, Aukrust P, Wallentin L; PLATO Investigators. ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial. Atherosclerosis. 2020 Jan;293:35-41. doi: 10.1016/j.atherosclerosis.2019.11.031. Epub 2019 Nov 29. PubMed 31835039 ↗
  • Andersen T, Ueland T, Ghukasyan Lakic T, Akerblom A, Bertilsson M, Aukrust P, Michelsen AE, James SK, Becker RC, Storey RF, Wallentin L, Siegbahn A, Kontny F. C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary Syndromes. Arterioscler Thromb Vasc Biol. 2019 Nov;39(11):2402-2410. doi: 10.1161/ATVBAHA.119.312633. Epub 2019 Sep 26. PubMed 31554419 ↗
  • Akerblom A, Wojdyla DM, Wallentin L, James SK, de Souza Brito F, Steg PG, Cannon CP, Katus HA, Himmelmann A, Storey RF, Becker RC, Lopes RD; PLATO Investigators. Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2019 Jul;213:57-65. doi: 10.1016/j.ahj.2019.04.006. Epub 2019 Apr 18. PubMed 31108273 ↗
  • Franchi F, James SK, Ghukasyan Lakic T, Budaj AJ, Cornel JH, Katus HA, Keltai M, Kontny F, Lewis BS, Storey RF, Himmelmann A, Wallentin L, Angiolillo DJ; PLATO Investigators. Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y12 Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial. J Am Heart Assoc. 2019 Mar 19;8(6):e011139. doi: 10.1161/JAHA.118.011139. PubMed 30857464 ↗
  • Lindholm D, James SK, Gabrysch K, Storey RF, Himmelmann A, Cannon CP, Mahaffey KW, Steg PG, Held C, Siegbahn A, Wallentin L. Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study. JAMA Cardiol. 2018 Dec 1;3(12):1160-1166. doi: 10.1001/jamacardio.2018.3811. PubMed 30427997 ↗
  • Inohara T, Pieper K, Wojdyla DM, Patel MR, Jones WS, Tricoci P, Mahaffey KW, James SK, Alexander JH, Lopes RD, Wallentin L, Ohman EM, Roe MT, Vemulapalli S. Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome. Am Heart J. 2018 Jul;201:25-32. doi: 10.1016/j.ahj.2018.03.013. Epub 2018 Mar 28. PubMed 29910052 ↗
  • Ueland T, Akerblom A, Ghukasyan T, Michelsen AE, Aukrust P, Becker RC, Bertilsson M, Himmelmann A, James SK, Siegbahn A, Storey RF, Kontny F, Wallentin L; PLATO (Platelet Inhibition and Patient Outcomes) Trial Investigators. Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial. J Am Heart Assoc. 2018 Jan 12;7(2):e007009. doi: 10.1161/JAHA.117.007009. PubMed 29330256 ↗
  • Bellavia A, Wallentin L, Orsini N, James SK, Cannon CP, Himmelmann A, Sundstrom J, Renlund H, Lytsy P. Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial. Open Heart. 2017 Jun 1;4(2):e000557. doi: 10.1136/openhrt-2016-000557. eCollection 2017. PubMed 28761675 ↗
  • Lindholm D, Hagstrom E, James SK, Becker RC, Cannon CP, Himmelmann A, Katus HA, Maurer G, Lopez-Sendon JL, Steg PG, Storey RF, Siegbahn A, Wallentin L. Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. J Am Heart Assoc. 2017 Apr 14;6(4):e005580. doi: 10.1161/JAHA.117.005580. PubMed 28411246 ↗
  • Lindholm D, James SK, Bertilsson M, Becker RC, Cannon CP, Giannitsis E, Harrington RA, Himmelmann A, Kontny F, Siegbahn A, Steg PG, Storey RF, Velders MA, Weaver WD, Wallentin L; PLATO Investigators. Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome. Clin Chem. 2017 Feb;63(2):573-584. doi: 10.1373/clinchem.2016.261271. Epub 2016 Dec 8. PubMed 27932413 ↗
  • Held P, Himmelmann A, Ditmarsch M. Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program. Future Cardiol. 2016 Jul;12(4):405-18. doi: 10.2217/fca-2016-0028. Epub 2016 May 10. PubMed 27160944 ↗
  • Johansson A, Eriksson N, Lindholm D, Varenhorst C, James S, Syvanen AC, Axelsson T, Siegbahn A, Barratt BJ, Becker RC, Himmelmann A, Katus HA, Steg PG, Storey RF, Wallentin L; PLATO Investigators. Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome. Hum Mol Genet. 2016 Apr 1;25(7):1447-56. doi: 10.1093/hmg/ddw012. Epub 2016 Jan 21. PubMed 26908625 ↗
  • Velders MA, Abtan J, Angiolillo DJ, Ardissino D, Harrington RA, Hellkamp A, Himmelmann A, Husted S, Katus HA, Meier B, Schulte PJ, Storey RF, Wallentin L, Gabriel Steg P, James SK; PLATO Investigators. Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. Heart. 2016 Apr;102(8):617-25. doi: 10.1136/heartjnl-2015-308963. Epub 2016 Feb 4. PubMed 26848185 ↗
  • Bui AH, Cannon CP, Steg PG, Storey RF, Husted S, Guo J, Im K, James SK, Michelson EL, Himmelmann A, Held C, Varenhorst C, Wallentin L, Scirica BM. Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circ Arrhythm Electrophysiol. 2016 Feb;9(2):e002951. doi: 10.1161/CIRCEP.115.002951. PubMed 26810596 ↗
  • Andell P, James SK, Cannon CP, Cyr DD, Himmelmann A, Husted S, Keltai M, Koul S, Santoso A, Steg PG, Storey RF, Wallentin L, Erlinge D; PLATO Investigators. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. J Am Heart Assoc. 2015 Oct 9;4(10):e002490. doi: 10.1161/JAHA.115.002490. PubMed 26452988 ↗
  • Hagstrom E, James SK, Bertilsson M, Becker RC, Himmelmann A, Husted S, Katus HA, Steg PG, Storey RF, Siegbahn A, Wallentin L; PLATO Investigators. Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. Eur Heart J. 2016 Apr 21;37(16):1325-33. doi: 10.1093/eurheartj/ehv491. Epub 2015 Sep 28. PubMed 26417057 ↗
  • Mahaffey KW, Hager R, Wojdyla D, White HD, Armstrong PW, Alexander JH, Tricoci P, Lopes RD, Ohman EM, Roe MT, Harrington RA, Wallentin L. Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes. J Am Heart Assoc. 2015 Jun 18;4(6):e001512. doi: 10.1161/JAHA.114.001512. PubMed 26089177 ↗
  • Kang HJ, Clare RM, Gao R, Held C, Himmelmann A, James SK, Lim ST, Santoso A, Yu CM, Wallentin L, Becker RC; PLATO Investigators. Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Am Heart J. 2015 Jun;169(6):899-905.e1. doi: 10.1016/j.ahj.2015.03.015. Epub 2015 Mar 31. PubMed 26027629 ↗
  • Velders MA, Wallentin L, Becker RC, van Boven AJ, Himmelmann A, Husted S, Katus HA, Lindholm D, Morais J, Siegbahn A, Storey RF, Wernroth L, James SK; PLATO Investigators. Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial. Am Heart J. 2015 Jun;169(6):879-889.e7. doi: 10.1016/j.ahj.2015.02.019. Epub 2015 Mar 5. PubMed 26027627 ↗
  • Varenhorst C, Eriksson N, Johansson A, Barratt BJ, Hagstrom E, Akerblom A, Syvanen AC, Becker RC, James SK, Katus HA, Husted S, Steg PG, Siegbahn A, Voora D, Teng R, Storey RF, Wallentin L; PLATO Investigators. Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. Eur Heart J. 2015 Aug 1;36(29):1901-12. doi: 10.1093/eurheartj/ehv116. Epub 2015 May 2. PubMed 25935875 ↗
  • Kholaif N, Zheng Y, Jagasia P, Himmelmann A, James SK, Steg PG, Storey RF, Westerhout CM, Armstrong PW. Baseline Q waves and time from symptom onset to ST-segment elevation myocardial infarction: insights from PLATO on the influence of sex. Am J Med. 2015 Aug;128(8):914.e11-9. doi: 10.1016/j.amjmed.2015.03.005. Epub 2015 Mar 26. PubMed 25818495 ↗
  • Cowper PA, Pan W, Anstrom KJ, Kaul P, Wallentin L, Davidson-Ray L, Nikolic E, Janzon M, Levin LA, Cannon CP, Harrington RA, Mark DB. Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study. J Am Coll Cardiol. 2015 Feb 10;65(5):465-76. doi: 10.1016/j.jacc.2014.11.034. PubMed 25660925 ↗
  • Janzon M, James S, Cannon CP, Storey RF, Mellstrom C, Nicolau JC, Wallentin L, Henriksson M. Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy. Heart. 2015 Jan;101(2):119-25. doi: 10.1136/heartjnl-2014-305864. Epub 2014 Sep 16. PubMed 25227704 ↗
  • Varenhorst C, Alstrom U, Braun OO, Storey RF, Mahaffey KW, Bertilsson M, Cannon CP, Scirica BM, Himmelmann A, James SK, Wallentin L, Held C. Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. Heart. 2014 Nov;100(22):1762-9. doi: 10.1136/heartjnl-2014-305619. Epub 2014 Jun 23. PubMed 24957530 ↗
  • Kotsia A, Brilakis ES, Held C, Cannon C, Steg GP, Meier B, Cools F, Claeys MJ, Cornel JH, Aylward P, Lewis BS, Weaver D, Brandrup-Wognsen G, Stevens SR, Himmelmann A, Wallentin L, James SK. Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2014 Jul;168(1):68-75.e2. doi: 10.1016/j.ahj.2014.04.001. Epub 2014 Apr 13. PubMed 24952862 ↗
  • Patel MR, Becker RC, Wojdyla DM, Emanuelsson H, Hiatt WR, Horrow J, Husted S, Mahaffey KW, Steg PG, Storey RF, Wallentin L, James SK. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. Eur J Prev Cardiol. 2015 Jun;22(6):734-42. doi: 10.1177/2047487314533215. Epub 2014 May 15. PubMed 24830710 ↗
  • Husted S, James SK, Bach RG, Becker RC, Budaj A, Heras M, Himmelmann A, Horrow J, Katus HA, Lassila R, Morais J, Nicolau JC, Steg PG, Storey RF, Wojdyla D, Wallentin L; PLATO study group. The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2014 Jun 14;35(23):1541-50. doi: 10.1093/eurheartj/ehu075. Epub 2014 Mar 28. PubMed 24682844 ↗
  • Mahaffey KW, Held C, Wojdyla DM, James SK, Katus HA, Husted S, Steg PG, Cannon CP, Becker RC, Storey RF, Khurmi NS, Nicolau JC, Yu CM, Ardissino D, Budaj A, Morais J, Montgomery D, Himmelmann A, Harrington RA, Wallentin L; PLATO Investigators. Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2014 Apr 22;63(15):1493-9. doi: 10.1016/j.jacc.2014.01.038. Epub 2014 Feb 19. PubMed 24561148 ↗
  • Wallentin L, Lindholm D, Siegbahn A, Wernroth L, Becker RC, Cannon CP, Cornel JH, Himmelmann A, Giannitsis E, Harrington RA, Held C, Husted S, Katus HA, Mahaffey KW, Steg PG, Storey RF, James SK; PLATO study group. Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2014 Jan 21;129(3):293-303. doi: 10.1161/CIRCULATIONAHA.113.004420. Epub 2013 Oct 29. PubMed 24170388 ↗
  • Brilakis ES, Held C, Meier B, Cools F, Claeys MJ, Cornel JH, Aylward P, Lewis BS, Weaver D, Brandrup-Wognsen G, Stevens SR, Himmelmann A, Wallentin L, James SK. Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial. Am Heart J. 2013 Sep;166(3):474-80. doi: 10.1016/j.ahj.2013.06.019. Epub 2013 Jul 26. PubMed 24016496 ↗
  • Steg PG, Harrington RA, Emanuelsson H, Katus HA, Mahaffey KW, Meier B, Storey RF, Wojdyla DM, Lewis BS, Maurer G, Wallentin L, James SK; PLATO Study Group. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation. 2013 Sep 3;128(10):1055-65. doi: 10.1161/CIRCULATIONAHA.113.002589. Epub 2013 Jul 30. PubMed 23900047 ↗
  • Kunadian V, James SK, Wojdyla DM, Zorkun C, Wu J, Storey RF, Steg PG, Katus H, Emanuelsson H, Horrow J, Maya J, Wallentin L, Harrington RA, Gibson CM. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). JACC Cardiovasc Interv. 2013 Jul;6(7):671-83. doi: 10.1016/j.jcin.2013.03.014. PubMed 23866179 ↗
  • James SK, Storey RF, Pieper KS, Cannon CP, Becker RC, Steg PG, Wallentin L, Harrington RA; PLATO Study Group. Response to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials". Stroke. 2013 Aug;44(8):e95-6. doi: 10.1161/STROKEAHA.113.002069. Epub 2013 Jun 25. No abstract available. PubMed 23800556 ↗
  • James SK, Pieper KS, Cannon CP, Storey RF, Becker RC, Steg PG, Wallentin L, Harrington RA; PLATO study group. Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. Stroke. 2013 May;44(5):1477-9. doi: 10.1161/STROKEAHA.111.000514. Epub 2013 Apr 9. No abstract available. PubMed 23572474 ↗
  • Kohli P, Wallentin L, Reyes E, Horrow J, Husted S, Angiolillo DJ, Ardissino D, Maurer G, Morais J, Nicolau JC, Oto A, Storey RF, James SK, Cannon CP. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. Circulation. 2013 Feb 12;127(6):673-80. doi: 10.1161/CIRCULATIONAHA.112.124248. Epub 2012 Dec 31. PubMed 23277305 ↗
  • Akerblom A, Wallentin L, Siegbahn A, Becker RC, Budaj A, Horrow J, Husted S, Katus H, Claeys MJ, Storey RF, Asenblad N, James SK. Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study. Am Heart J. 2012 Nov;164(5):728-34. doi: 10.1016/j.ahj.2012.08.017. Epub 2012 Oct 17. PubMed 23137503 ↗
  • Varenhorst C, Alstrom U, Scirica BM, Hogue CW, Asenblad N, Storey RF, Steg PG, Horrow J, Mahaffey KW, Becker RC, James S, Cannon CP, Brandrup-Wognsen G, Wallentin L, Held C. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol. 2012 Oct 23;60(17):1623-30. doi: 10.1016/j.jacc.2012.07.021. Epub 2012 Sep 26. PubMed 23021325 ↗
  • Husted S, James S, Becker RC, Horrow J, Katus H, Storey RF, Cannon CP, Heras M, Lopes RD, Morais J, Mahaffey KW, Bach RG, Wojdyla D, Wallentin L; PLATO study group. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):680-8. doi: 10.1161/CIRCOUTCOMES.111.964395. PubMed 22991347 ↗
  • Cornel JH, Becker RC, Goodman SG, Husted S, Katus H, Santoso A, Steg G, Storey RF, Vintila M, Sun JL, Horrow J, Wallentin L, Harrington R, James S. Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2012 Sep;164(3):334-342.e1. doi: 10.1016/j.ahj.2012.06.005. Epub 2012 Jul 26. PubMed 22980299 ↗
  • Nikolic E, Janzon M, Hauch O, Wallentin L, Henriksson M; PLATO Health Economic Substudy Group. Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. Eur Heart J. 2013 Jan;34(3):220-8. doi: 10.1093/eurheartj/ehs149. Epub 2012 Jun 19. PubMed 22719022 ↗
  • James SK, Storey RF, Khurmi NS, Husted S, Keltai M, Mahaffey KW, Maya J, Morais J, Lopes RD, Nicolau JC, Pais P, Raev D, Lopez-Sendon JL, Stevens SR, Becker RC; PLATO Study Group. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation. 2012 Jun 12;125(23):2914-21. doi: 10.1161/CIRCULATIONAHA.111.082727. Epub 2012 May 9. PubMed 22572911 ↗
  • Siha H, Das D, Fu Y, Zheng Y, Westerhout CM, Storey RF, James S, Wallentin L, Armstrong PW. Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial. CMAJ. 2012 Jul 10;184(10):1135-42. doi: 10.1503/cmaj.111683. Epub 2012 Apr 30. PubMed 22546885 ↗
  • Goodman SG, Clare R, Pieper KS, Nicolau JC, Storey RF, Cantor WJ, Mahaffey KW, Angiolillo DJ, Husted S, Cannon CP, James SK, Kilhamn J, Steg PG, Harrington RA, Wallentin L; Platelet Inhibition and Patient Outcomes Trial Investigators. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation. 2012 Feb 28;125(8):978-86. doi: 10.1161/CIRCULATIONAHA.111.032912. Epub 2012 Jan 18. PubMed 22261200 ↗
  • Armstrong PW, Siha H, Fu Y, Westerhout CM, Steg PG, James SK, Storey RF, Horrow J, Katus H, Clemmensen P, Harrington RA, Wallentin L. ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. Circulation. 2012 Jan 24;125(3):514-21. doi: 10.1161/CIRCULATIONAHA.111.047530. Epub 2011 Dec 16. PubMed 22179530 ↗
  • Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK, Cornel JH, French J, Held C, Horrow J, Husted S, Lopez-Sendon J, Lassila R, Mahaffey KW, Storey RF, Harrington RA, Wallentin L. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2011 Dec;32(23):2933-44. doi: 10.1093/eurheartj/ehr422. Epub 2011 Nov 16. Erratum In: Eur Heart J. 2012 Nov;33(21):2750. PubMed 22090660 ↗
  • Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF, Angiolillo DJ, Held C, Cannon CP, James S, Pieper KS, Horrow J, Harrington RA, Wallentin L; PLATO Investigators. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011 Aug 2;124(5):544-54. doi: 10.1161/CIRCULATIONAHA.111.047498. Epub 2011 Jun 27. PubMed 21709065 ↗
  • James SK, Roe MT, Cannon CP, Cornel JH, Horrow J, Husted S, Katus H, Morais J, Steg PG, Storey RF, Stevens S, Wallentin L, Harrington RA; PLATO Study Group. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ. 2011 Jun 17;342:d3527. doi: 10.1136/bmj.d3527. PubMed 21685437 ↗
  • Scirica BM, Cannon CP, Emanuelsson H, Michelson EL, Harrington RA, Husted S, James S, Katus H, Pais P, Raev D, Spinar J, Steg PG, Storey RF, Wallentin L; PLATO Investigators. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. J Am Coll Cardiol. 2011 May 10;57(19):1908-16. doi: 10.1016/j.jacc.2010.11.056. PubMed 21545948 ↗
  • Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP, Emanuelsson H, Finkelstein A, Husted S, Katus H, Kilhamn J, Olofsson S, Storey RF, Weaver WD, Wallentin L; PLATO Study Group. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation. 2010 Nov 23;122(21):2131-41. doi: 10.1161/CIRCULATIONAHA.109.927582. Epub 2010 Nov 8. PubMed 21060072 ↗
  • James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, Harrington RA, Horrow J, Katus H, Keltai M, Lewis BS, Parikh K, Storey RF, Szummer K, Wojdyla D, Wallentin L. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010 Sep 14;122(11):1056-67. doi: 10.1161/CIRCULATIONAHA.109.933796. Epub 2010 Aug 30. PubMed 20805430 ↗
  • Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H, Husted S, Katus H, Keltai M, Khurmi NS, Kontny F, Lewis BS, Steg PG, Storey RF, Wojdyla D, Wallentin L; PLATelet inhibition and patient Outcomes Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010 Jan 23;375(9711):283-93. doi: 10.1016/S0140-6736(09)62191-7. Epub 2010 Jan 13. PubMed 20079528 ↗
  • Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators; Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30. PubMed 19717846 ↗
  • Molecule of the month. Ticagrelor. Drug News Perspect. 2007 May;20(4):264. No abstract available. PubMed 17637939 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2006, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2006
First posted
Oct 25, 2006
Start
Oct 2006
Primary completionActual
Mar 2009
CompletionActual
Mar 2009
Results first posted
Mar 13, 2012
Last update
Mar 13, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00391872
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 25, 2006
Start date
Oct 2006
Primary completion
Mar 2009
Completion
Mar 2009
Results posted
Mar 13, 2012
Last update
Mar 13, 2012

Study contacts

Robert Harrington, MD
principal investigator · Duke Clinical Research Institute
Lars Wallentin, MD
principal investigator · Uppsala Clinical Research Centre
Jonathan C. Fox, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion